Komori
Other Disclosures7044PIALA INC.Information and Communications, Services and Others

Notice regarding the launch of nationwide sales of consolidated subsidiary 株式会社P2C’s own-brand product 良朝丸 (Yoichomaru), a designated quasi-drug, at MatsukiyoCocokara & Co. stores

良朝丸 (Yoichomaru), a designated quasi-drug manufactured by consolidated subsidiary 株式会社P2C, will be sold at MatsukiyoCocokara & Co. stores nationwide on a rolling basis from 8 October 2026. The sales channel, which had been centered on e-commerce, will be expanded to physical stores nationwide.

Worth reading
76Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1855
Location
Wording
Definitive
How definitive the wording is.

Announced details

良朝丸 (Yoichomaru), a designated quasi-drug
Applicable field (uses covered by this announcement)

Stomach discomfort and nausea caused by overeating or overdrinking (queasiness, stomach upset, hangover-related nausea, nausea and queasiness)

Launch dateTo begin on a rolling basis from 8 October 2026 (planned; phased rollout)
What the company reported numerically
Usage history

Achieved high rankings on major e-commerce marketplaces: Amazon bestseller in the Kampo medicine and pharmaceuticals category (4–6 July 2026) and No. 1 in the daily ranking for the turmeric category on Rakuten Ichiba (19 November 2025).

Relationship between the counterparty and the company
PIALA INC.7044
Relationship with the Company

A business relationship under which 株式会社P2C’s products are sold at MatsukiyoCocokara & Co. group stores. 株式会社P2C is our consolidated subsidiary.

CounterpartyMatsukiyoCocokara & Co.

A group operating drugstores nationwide. The document does not state its location, representative, capital or year of establishment.

Location (as indicated in this announcement)

株式会社P2C: 13th Floor, Ebisu Garden Place Tower, 4-20-3 Ebisu, Shibuya-ku, Tokyo

1,855 MatsukiyoCocokara & Co. stores nationwide. マツモトキヨシ operates in 45 prefectures, ココカラファイン in 34 prefectures, ドラッグ新生堂/くすりのハッピー in Fukuoka, Kumamoto and Nagasaki, and ぱぱす in Tokyo.
Offering price

45 tablets (15 doses): ¥1,490 (including tax)

135 tablets (45 doses): ¥3,980 (including tax)

270 tablets (90 doses): ¥6,980 (including tax)

Impact on Business Performance

No specific amount of impact on financial results is stated. The company aims to expand sales and accelerate growth in its Business Creation business.

The company does not address Contract Value.

Source (materials cited by the company)

Amazon Kampo medicine and pharmaceuticals category rankings and Rakuten Ichiba daily turmeric category rankings

Announced details
ItemDetails
Names of Products / Services Covered良朝丸 (Yoichomaru), a designated quasi-drug
CounterpartyMatsukiyoCocokara & Co.
Counterparty overviewA group operating drugstores nationwide. The document does not state its location, representative, capital or year of establishment.
Relationship with the CompanyA business relationship under which 株式会社P2C’s products are sold at MatsukiyoCocokara & Co. group stores. 株式会社P2C is our consolidated subsidiary.
Offering price45 tablets (15 doses): ¥1,490 (including tax), 135 tablets (45 doses): ¥3,980 (including tax), 270 tablets (90 doses): ¥6,980 (including tax)
Launch dateTo begin on a rolling basis from 8 October 2026 (planned; phased rollout)
Applicable areaStomach discomfort and nausea caused by overeating or overdrinking (queasiness, stomach upset, hangover-related nausea, nausea and queasiness)
Location株式会社P2C: 13th Floor, Ebisu Garden Place Tower, 4-20-3 Ebisu, Shibuya-ku, Tokyo
Location scale1,855 MatsukiyoCocokara & Co. stores nationwide. マツモトキヨシ operates in 45 prefectures, ココカラファイン in 34 prefectures, ドラッグ新生堂/くすりのハッピー in Fukuoka, Kumamoto and Nagasaki, and ぱぱす in Tokyo.
Usage historyAchieved high rankings on major e-commerce marketplaces: Amazon bestseller in the Kampo medicine and pharmaceuticals category (4–6 July 2026) and No. 1 in the daily ranking for the turmeric category on Rakuten Ichiba (19 November 2025).
Impact on Business PerformanceNo specific amount of impact on financial results is stated. The company aims to expand sales and accelerate growth in its Business Creation business.
SourceAmazon Kampo medicine and pharmaceuticals category rankings and Rakuten Ichiba daily turmeric category rankings
Items this document does not state (6)
Contract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateQuantitative Effects

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To expand sales to customer segments that had no opportunity to purchase the product online, leveraging its e-commerce sales track record, and to establish an in-store sales structure ahead of the peak demand season for year-end parties and the year-end/New Year period.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice regarding the launch of nationwide sales of consolidated subsidiary 株式会社P2C’s own-brand product 良朝丸 (Yoichomaru), a designated quasi-drug, at MatsukiyoCocokara & Co. stores | PIALA INC. (7044) timely disclosure | Komori